# Medtronic (MDT.US)

Canonical: https://gigainvestors.com/s/MDT

Analysis as of: 2026-10-16T07:30:08.494Z. Financial observations: FY1997–FY2027.

Listing currency: USD. Reporting currency: USD.

## Verdict

A wonderful business at too high a price

Quality tests for Buy: pass (profit record: pass; earnings resilience is evidence only). Published buy qualification: no.

Share price: $95.45 per share; close as of 2026-10-15.

Estimated value: low $57.68 per share, central $64.77 per share, high $74.20 per share. Buy at or below the central value $64.77 per share. Valuation as of 2026-10-16T07:30:08.494Z; scenarios are not confidence intervals.

Expected annual return: 7.5% at the stated quote. About 7.5% a year at today's price (required return 10.0%). required return 10.0% a year (10% floor; US 10-year bond 5.1% + 4 points).

## Checklist

### understandable: pass

- 2 revenue declines in the last 10 years (informational)

- Financial history: 10 years

- Years with declining revenue: 2

- Years with a net loss: 0

- Operating margin variation: 0.11×

Chart: Operating margin; fiscal year observations.

- FY2018: 0.22×

- FY2019: 0.21×

- FY2020: 0.17×

- FY2021: 0.15×

- FY2022: 0.18×

- FY2023: 0.18×

- FY2024: 0.16×

- FY2025: 0.18×

- FY2026: 0.18×

- LTM to Jul 2026: 0.18×

### moat: pass

- ROIC, median of available years: 18.0%

- ROIC, second-lowest year: 15.0%

- Typical minus recent gross margin: 1.5 pp

- Typical gross margin (annual median): 66.5%

- Recent gross margin (lower of latest and 3-year median): 65.0%

- Years with nonpositive capital: 0

- Capital spending / revenue: 4.4%

- ROIC including acquisitions, ten-year median: 8.2%

Chart: ROIC excluding acquisitions; fiscal year observations.

- FY2018: 16.8%

- FY2019: 21.9%

- FY2020: 19.4%

- FY2021: 16.7%

- FY2022: 20.6%

- FY2023: 14.6%

- FY2024: 15.0%

- FY2025: 19.2%

- FY2026: 19.9%

- LTM to Jul 2026: 20.5%

### economics: pass

- Owner earnings / net income, 5-yr: 1.26×

- Cash conversion uses consolidated totals: No

- Owner earnings, five-year total: $28B

- Net income, five-year total: $22B

- Return on incremental invested capital: >100%

- Working capital / revenue, annual change: 0.3 pp

- Working capital / revenue, change between three-year averages: 1.9 pp

- Working capital / revenue, final three-year average: 27.8%

Chart: Annual owner cash / profit; fiscal year observations.

- FY2023: 1.33×

- FY2024: 1.29×

- FY2025: 1.21×

- FY2026: 1.22×

- LTM to Jul 2026: 1.10×

### management: pass

- Historical market-dollar context (not the management verdict): 2017 to 2026 (9 years)

- buybacks leaned toward cheaper years (informational)

- ROIC first 3 years vs last 3 years: 16.8% vs 19.2%

- Per-share earnings: 2.48 to 3.61 (three-year endpoint medians)

- Management verdict uses per-share economic progress: Yes

- Ordinary dilution, 10-year annual growth: -1.0%

- Ordinary dilution, 5-year annual growth: -1.0%

- Market cap gain: -$10B

- Cumulative retained earnings: $9.3B

- Diluted shares, 10-year annual growth: -1.0%

- Diluted shares, 5-year annual growth: -1.0%

- $1 test, starting fiscal year: FY2017

- $1 test, ending fiscal year: FY2026

- Per-share value growth: 4.8%

- Per-share value change: $1.13

- Per-share value, starting three-year median: $2.48

- Per-share value, ending three-year median: $3.61

- Buybacks concentrated in cheaper years (correlation): 0.33

- Average buyback yield: 1.7%

- Buyback history: 10 years

- Debt-funded buybacks: No

- Acquisition spending: $970M

- Cumulative net income, 10 years: $42B

- ROIC, first three-year median: 16.8%

- ROIC, last three-year median: 19.2%

Chart: Earnings per share; fiscal year observations.

- FY2017: $2.89

- FY2018: $2.27

- FY2019: $3.41

- FY2020: $3.54

- FY2021: $2.66

- FY2022: $3.73

- FY2023: $2.82

- FY2024: $2.76

- FY2025: $3.61

- FY2026: $3.73

### accounting: pass

- Sloan accruals: -2.7%

- Receivables to sales index (DSRI): 0.94×

- Restructuring years, last five: 2

- Stock compensation / operating cash flow: 6.2%

- Earnings backed by cash: Yes

- Operating cash / earnings: 1.53×

- Accounting red flags: 0

- Goodwill and intangibles / equity: 1.07×

Chart: Sloan accruals; fiscal year observations.

- FY2017: -2.9%

- FY2018: -1.7%

- FY2019: -2.6%

- FY2020: -2.7%

- FY2021: -2.8%

- FY2022: -2.5%

- FY2023: -2.5%

- FY2024: -3.5%

- FY2025: -2.6%

- FY2026: -2.7%

## Holders

- [David Hoeft](https://gigainvestors.com/DAC): tracked 13F investor; follow the investor page for holding quarter and amounts.

- [Matthew McLennan](https://gigainvestors.com/FE): tracked 13F investor; follow the investor page for holding quarter and amounts.

- [Mark Hillman](https://gigainvestors.com/HCM): tracked 13F investor; follow the investor page for holding quarter and amounts.

- [David Katz](https://gigainvestors.com/MAVFX): tracked 13F investor; follow the investor page for holding quarter and amounts.

- [Andrew Adams](https://gigainvestors.com/MPF): tracked 13F investor; follow the investor page for holding quarter and amounts.

- [Richard Pzena](https://gigainvestors.com/PIM): tracked 13F investor; follow the investor page for holding quarter and amounts.

- [Harry Burn](https://gigainvestors.com/SSHFX): tracked 13F investor; follow the investor page for holding quarter and amounts.

## Price story

Down 20% since Oct 2021 · "Looking ahead, we anticipate incurring additional costs related to current imposed and proposed tariffs." (SEC filing, Jun 2026) · sales +8.4%

Story as of 2026-10-16T09:59:08.779Z; price observation 2026-10-15.

Price needs cash profits to grow 6.2% a year for ten years

- 2025-11-19: Medtronic raises FY26 outlook amid cardiac ablation surge ([finance.yahoo.com](https://finance.yahoo.com/news/medtronic-raises-fy26-outlook-amid-124432363.html))

- 2026-01-12: Medtronic gains FDA clearance for MiniMed Go insulin dosing system app ([seekingalpha.com](https://seekingalpha.com/news/4538460-medtronic-gains-fda-clearance-minimed-go-insulin-dosing-system-app?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news))

- 2026-02-15: Medtronic Faces Antitrust Hit While Betting On Stealth AXiS Growth ([finance.yahoo.com](https://finance.yahoo.com/news/medtronic-faces-antitrust-hit-while-081052020.html))

- 2026-03-25: Medtronic lowers earnings forecast after MiniMed IPO ([finance.yahoo.com](https://finance.yahoo.com/sectors/healthcare/articles/medtronic-lowers-earnings-forecast-minimed-114323074.html))

- 2026-07-10: Medtronic gains on reimbursement hopes for blood pressure therapy ([seekingalpha.com](https://seekingalpha.com/news/4612988-medtronic-gains-coverage-hopes-renal-denervation?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news))

- 2026-08-08: Medtronic (MDT) Wins Expanded CE Mark For Affera System In Ventricular Arrhythmias ([finance.yahoo.com](https://finance.yahoo.com/healthcare/articles/medtronic-mdt-wins-expanded-ce-020910766.html))

### Sales · FY2025–2026

sales +8.4%; source https://www.sec.gov/Archives/edgar/data/1613103/000162828026044354/mdt-20260424.htm; observed 2026-06-18.

- FY2017: $30B 

- FY2018: $30B 

- FY2019: $31B 

- FY2020: $29B 

- FY2021: $30B 

- FY2022: $32B 

- FY2023: $31B 

- FY2024: $32B 

- FY2025: $34B 

- FY2026: $36B 

### Gross margin · FY2026

gross margin 65%; source https://www.sec.gov/Archives/edgar/data/1613103/000162828026044354/mdt-20260424.htm; observed 2026-06-18.

- FY2017: 68.7% 

- FY2018: 69.7% 

- FY2019: 70.0% 

- FY2020: 67.4% 

- FY2021: 65.2% 

- FY2022: 68.0% 

- FY2023: 65.7% 

- FY2024: 65.3% 

- FY2025: 65.3% 

- FY2026: 65.0% 

## Owner memo

Memo as of 2026-10-16T08:06:05.509Z.

### How it makes money

Operates in medical devices; annual sales are USD 36.4 billion.

- Source: https://www.sec.gov/Archives/edgar/data/1613103/000162828026044354/mdt-20260424.htm (filed 2026-06-18); FY2026: revenue 36364000000; grossProfit 23643000000; margin = grossProfit / revenue.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-10-16); MDT.US: Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring sys

### Why customers stay

Margins ranged from 65% to 65.3% during 2024–26; it earns 18% on its capital.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-06-18); FY2024: grossProfit / revenue = 65.3%.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-06-18); FY2025: grossProfit / revenue = 65.3%.

- Source: https://www.sec.gov/Archives/edgar/data/1613103/000162828026044354/mdt-20260424.htm (filed 2026-06-18); FY2026: grossProfit / revenue = 65%.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-06-18); 10-year return on capital observations [[2017,0.14955860131986556],[2018,0.16785283708629875],[2019,0.2190817611716556],[2020,0.19361487169125075],[2021,0.1668967142964293],[2022,0.20619681126289602],[2023,0.14621768837798463],[2024,0.15007770481565377],[2025,0.19214398191388002],[2026,0.19900561444717765]]; median 0.17999840950008938. ROIC follows the displayed moat series; financial companies use return on tangible equity.

### Where the cash goes

Paid dividends in 10 of 10 years; bought back USD 1 billion of shares.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-06-18); FY2017: growth capex 0; upkeep 1254000000; owner earnings 5691000000. Growth capex / owner earnings = 0.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-06-18); FY2018: growth capex 0; upkeep 1068000000; owner earnings 4680000000. Growth capex / owner earnings = 0.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-06-18); FY2019: growth capex 0; upkeep 1134000000; owner earnings 6156000000. Growth capex / owner earnings = 0.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-06-18); FY2020: growth capex 0; upkeep 1213000000; owner earnings 6239000000. Growth capex / owner earnings = 0.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-06-18); FY2021: growth capex 0; upkeep 1355000000; owner earnings 4953000000. Growth capex / owner earnings = 0.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-06-18); FY2022: growth capex 0; upkeep 1368000000; owner earnings 6378000000. Growth capex / owner earnings = 0.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-06-18); FY2023: growth capex 0; upkeep 1459000000; owner earnings 4996000000. Growth capex / owner earnings = 0.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-06-18); FY2024: growth capex 0; upkeep 1587000000; owner earnings 4736000000. Growth capex / owner earnings = 0.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-06-18); FY2025: growth capex 0; upkeep 1859000000; owner earnings 5664000000. Growth capex / owner earnings = 0.

- Source: https://www.sec.gov/Archives/edgar/data/1613103/000162828026044354/mdt-20260424.htm (filed 2026-06-18); FY2026: growth capex 0; upkeep 1904000000; owner earnings 5854000000. Growth capex / owner earnings = 0.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-06-18); Dividend observations: [[2017,2376000000],[2018,2494000000],[2019,2693000000],[2020,2894000000],[2021,3121000000],[2022,3383000000],[2023,3616000000],[2024,3666000000],[2025,3589000000],[2026,3639000000]]. Zero only counted when supported by a complete cash-flow statement.

- Source: https://www.sec.gov/Archives/edgar/data/1613103/000162828026044354/mdt-20260424.htm (filed 2026-06-18); FY2026: cash repurchases 1035000000 USD.

### Are managers owners

Insiders own 0.3% of the company.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-10-16); MDT.US SharesStats.PercentInsiders = 0.349 percentage points; cache date 2026-10-16.

### What could break it

"Laws and regulations governing international business operations could adversely impact our business." (SEC filing, Jun 2026)

- Source: https://www.sec.gov/Archives/edgar/data/1613103/000162828026044354/mdt-20260424.htm (filed 2026-06-18); Laws and regulations governing international business operations could adversely impact our business.

### What the price says

The price assumes cash profits grow 6.2% yearly over ten years; actual growth was 2%.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-06-18); Ten-year compound average after fade. Initial solved rate 0.07565737759037627. Price 95.45; FX 1; discount 0.1; same standard ten-year fade to terminal 0.03. FY2016 owner earnings/share 3.7253664352338873 → FY2026 4.544678208213648. Closing-price date 2026-10-15.

## Monthly share-price history (USD per share)

- 2016-10: $82.02 per share

- 2016-11: $73.01 per share

- 2016-12: $71.23 per share

- 2017-01: $76.02 per share

- 2017-02: $80.91 per share

- 2017-03: $80.56 per share

- 2017-04: $83.09 per share

- 2017-05: $84.28 per share

- 2017-06: $88.75 per share

- 2017-07: $83.97 per share

- 2017-08: $80.62 per share

- 2017-09: $77.77 per share

- 2017-10: $80.52 per share

- 2017-11: $82.13 per share

- 2017-12: $80.75 per share

- 2018-01: $85.89 per share

- 2018-02: $79.89 per share

- 2018-03: $80.22 per share

- 2018-04: $80.13 per share

- 2018-05: $86.32 per share

- 2018-06: $85.61 per share

- 2018-07: $90.23 per share

- 2018-08: $96.41 per share

- 2018-09: $98.37 per share

- 2018-10: $89.82 per share

- 2018-11: $97.53 per share

- 2018-12: $90.96 per share

- 2019-01: $88.39 per share

- 2019-02: $90.50 per share

- 2019-03: $91.08 per share

- 2019-04: $88.81 per share

- 2019-05: $92.58 per share

- 2019-06: $97.39 per share

- 2019-07: $101.94 per share

- 2019-08: $107.89 per share

- 2019-09: $108.62 per share

- 2019-10: $108.90 per share

- 2019-11: $111.39 per share

- 2019-12: $113.45 per share

- 2020-01: $115.44 per share

- 2020-02: $100.67 per share

- 2020-03: $90.18 per share

- 2020-04: $97.63 per share

- 2020-05: $98.58 per share

- 2020-06: $91.70 per share

- 2020-07: $96.48 per share

- 2020-08: $107.47 per share

- 2020-09: $103.92 per share

- 2020-10: $100.57 per share

- 2020-11: $113.70 per share

- 2020-12: $117.14 per share

- 2021-01: $111.33 per share

- 2021-02: $116.97 per share

- 2021-03: $118.13 per share

- 2021-04: $130.92 per share

- 2021-05: $126.59 per share

- 2021-06: $124.13 per share

- 2021-07: $131.31 per share

- 2021-08: $133.48 per share

- 2021-09: $125.35 per share

- 2021-10: $119.86 per share

- 2021-11: $106.70 per share

- 2021-12: $103.45 per share

- 2022-01: $103.49 per share

- 2022-02: $104.99 per share

- 2022-03: $110.95 per share

- 2022-04: $104.36 per share

- 2022-05: $100.15 per share

- 2022-06: $89.75 per share

- 2022-07: $92.52 per share

- 2022-08: $87.92 per share

- 2022-09: $80.75 per share

- 2022-10: $87.34 per share

- 2022-11: $79.04 per share

- 2022-12: $77.72 per share

- 2023-01: $83.69 per share

- 2023-02: $82.80 per share

- 2023-03: $80.62 per share

- 2023-04: $90.95 per share

- 2023-05: $82.76 per share

- 2023-06: $88.10 per share

- 2023-07: $87.76 per share

- 2023-08: $81.50 per share

- 2023-09: $78.36 per share

- 2023-10: $70.56 per share

- 2023-11: $79.27 per share

- 2023-12: $82.38 per share

- 2024-01: $87.54 per share

- 2024-02: $83.36 per share

- 2024-03: $87.15 per share

- 2024-04: $80.24 per share

- 2024-05: $81.37 per share

- 2024-06: $78.71 per share

- 2024-07: $80.32 per share

- 2024-08: $88.58 per share

- 2024-09: $90.03 per share

- 2024-10: $89.25 per share

- 2024-11: $86.54 per share

- 2024-12: $79.88 per share

- 2025-01: $90.82 per share

- 2025-02: $92.02 per share

- 2025-03: $89.86 per share

- 2025-04: $84.76 per share

- 2025-05: $82.98 per share

- 2025-06: $87.17 per share

- 2025-07: $90.24 per share

- 2025-08: $92.81 per share

- 2025-09: $95.24 per share

- 2025-10: $90.70 per share

- 2025-11: $105.33 per share

- 2025-12: $96.06 per share

- 2026-01: $102.96 per share

- 2026-02: $97.66 per share

- 2026-03: $86.65 per share

- 2026-04: $80.97 per share

- 2026-05: $73.81 per share

- 2026-06: $78.23 per share

- 2026-07: $85.39 per share

- 2026-08: $90.65 per share

- 2026-09: $86.29 per share

- 2026-10: $93.01 per share

## Annual estimated value (USD per share)

- FY2017: low $54.13 per share, central $60.29 per share, high $68.50 per share

- FY2018: low $51.85 per share, central $57.93 per share, high $66.02 per share

- FY2019: low $52.13 per share, central $58.38 per share, high $66.70 per share

- FY2020: low $52.48 per share, central $58.66 per share, high $66.88 per share

- FY2021: low $54.11 per share, central $60.54 per share, high $69.08 per share

- FY2022: low $58.94 per share, central $66.05 per share, high $75.52 per share

- FY2023: low $57.05 per share, central $64.16 per share, high $73.62 per share

- FY2024: low $49.27 per share, central $55.30 per share, high $63.32 per share

- FY2025: low $53.17 per share, central $59.61 per share, high $68.19 per share

- FY2026: low $56.27 per share, central $63.12 per share, high $72.23 per share

Historical values use today's bond yield for every fiscal year

Historical values use today's FX rate into trading currency for every fiscal year

Historical values use current restated fundamentals and current commodity classification; they are not point-in-time estimates

Prior published observations retained from 2026-10-15T06:35:53.077Z where newer inputs omit a numeric field or fiscal period.

## Sources

[Original 10-K filing](https://www.sec.gov/Archives/edgar/data/1613103/000162828026044354/mdt-20260424.htm); period 2026-04-24, filed 2026-06-18.

Estimates depend on assumptions and are not guarantees or investment advice. Underlying data remains subject to its source licenses; public reading does not grant bulk redistribution rights.

## Reported holder observations

- [David Hoeft](https://gigainvestors.com/DAC): 7,875,898 MDT shares; USD 616,132,000 reported position value; 0.32% of portfolio; add; quarter 2026 Q2.
- [Matthew McLennan](https://gigainvestors.com/FE): 13,783,983 MDT shares; USD 1,078,321,000 reported position value; 1.78% of portfolio; add; quarter 2026 Q2.
- [Mark Hillman](https://gigainvestors.com/HCM): 5,707 MDT shares; USD 446,000 reported position value; 0.32% of portfolio; add; quarter 2026 Q2.
- [David Katz](https://gigainvestors.com/MAVFX): 426,624 MDT shares; USD 36,813,000 reported position value; 3.03% of portfolio; reduce; quarter 2026 Q3.
- [Andrew Adams](https://gigainvestors.com/MPF): 363,349 MDT shares; USD 28,425,000 reported position value; 0.26% of portfolio; reduce; quarter 2026 Q2.
- [Richard Pzena](https://gigainvestors.com/PIM): 3,147,999 MDT shares; USD 246,268,000 reported position value; 0.72% of portfolio; reduce; quarter 2026 Q2.
- [Harry Burn](https://gigainvestors.com/SSHFX): 838,573 MDT shares; USD 65,602,000 reported position value; 2.02% of portfolio; add; quarter 2026 Q2.

# MDT — Medtronic plc

Held by 1 investor · USD 36,813,000 total · 2026 Q3 · reported price USD 86.29 (split-adjusted).
Page: https://gigainvestors.com/s/MDT

## Holders (2026 Q3)

| Investor | Value | % of their portfolio | This quarter |
|---|---:|---:|---|
| David Katz (https://gigainvestors.com/MAVFX) | USD 36,813,000 | 3.0% | reduce -1.63% |

## Total held by quarter

- 2009 Q1: USD 719,068 · 1 holder · USD 86.43
- 2009 Q2: USD 851,072 · 1 holder · USD 102.29
- 2009 Q3: USD 897,920 · 1 holder · USD 107.92
- 2009 Q4: USD 1,161,072 · 1 holder · USD 128.98
- 2010 Q1: USD 1,189,056 · 1 holder · USD 132.09
- 2010 Q2: USD 958,056 · 1 holder · USD 106.43
- 2010 Q3: USD 453,060 · 1 holder · USD 98.42
- 2010 Q4: USD 0 · 0 holders
- 2011 Q1: USD 0 · 0 holders
- 2011 Q2: USD 0 · 0 holders
- 2011 Q3: USD 0 · 0 holders
- 2011 Q4: USD 0 · 0 holders
- 2012 Q1: USD 0 · 0 holders
- 2012 Q2: USD 0 · 0 holders
- 2012 Q3: USD 0 · 0 holders
- 2012 Q4: USD 0 · 0 holders
- 2013 Q1: USD 0 · 0 holders
- 2013 Q2: USD 0 · 0 holders
- 2013 Q3: USD 0 · 0 holders
- 2013 Q4: USD 0 · 0 holders
- 2014 Q1: USD 0 · 0 holders
- 2014 Q2: USD 0 · 0 holders
- 2014 Q3: USD 0 · 0 holders
- 2014 Q4: USD 0 · 0 holders
- 2015 Q1: USD 0 · 0 holders
- 2015 Q2: USD 0 · 0 holders
- 2015 Q3: USD 0 · 0 holders
- 2015 Q4: USD 0 · 0 holders
- 2016 Q1: USD 0 · 0 holders
- 2016 Q2: USD 0 · 0 holders
- 2016 Q3: USD 0 · 0 holders
- 2016 Q4: USD 0 · 0 holders
- 2017 Q1: USD 0 · 0 holders
- 2017 Q2: USD 0 · 0 holders
- 2017 Q3: USD 0 · 0 holders
- 2017 Q4: USD 0 · 0 holders
- 2018 Q1: USD 0 · 0 holders
- 2018 Q2: USD 0 · 0 holders
- 2018 Q3: USD 497,021 · 1 holder · USD 98.42
- 2018 Q4: USD 458,995 · 1 holder · USD 90.89
- 2019 Q1: USD 460,005 · 1 holder · USD 91.09
- 2019 Q2: USD 497,018 · 1 holder · USD 97.34
- 2019 Q3: USD 555,022 · 1 holder · USD 108.70
- 2019 Q4: USD 494,014 · 1 holder · USD 113.41
- 2020 Q1: USD 275,987 · 1 holder · USD 90.31
- 2020 Q2: USD 0 · 0 holders
- 2020 Q3: USD 23,828,025 · 1 holder · USD 103.92
- 2020 Q4: USD 26,590,663 · 1 holder · USD 117.14
- 2021 Q1: USD 26,546,646 · 1 holder · USD 118.13
- 2021 Q2: USD 23,848,725 · 1 holder · USD 124.13
- 2021 Q3: USD 23,877,545 · 1 holder · USD 125.35
- 2021 Q4: USD 19,641,948 · 1 holder · USD 103.45
- 2022 Q1: USD 34,310,844 · 2 holders · USD 110.95
- 2022 Q2: USD 32,856,039 · 2 holders · USD 89.75
- 2022 Q3: USD 27,105,110 · 2 holders · USD 80.75
- 2022 Q4: USD 179,225,506 · 2 holders · USD 77.72
- 2023 Q1: USD 454,713,730 · 2 holders · USD 80.62
- 2023 Q2: USD 498,088,767 · 2 holders · USD 88.10
- 2023 Q3: USD 490,245,314 · 2 holders · USD 78.36
- 2023 Q4: USD 789,084,161 · 2 holders · USD 82.38
- 2024 Q1: USD 2,357,054,646 · 6 holders · USD 87.15
- 2024 Q2: USD 2,179,947,249 · 6 holders · USD 78.71
- 2024 Q3: USD 2,465,995,274 · 6 holders · USD 90.03
- 2024 Q4: USD 2,138,200,361 · 5 holders · USD 79.88
- 2025 Q1: USD 2,409,564,960 · 6 holders · USD 89.86
- 2025 Q2: USD 2,367,202,484 · 6 holders · USD 87.17
- 2025 Q3: USD 2,304,148,862 · 6 holders · USD 95.24
- 2025 Q4: USD 2,067,030,039 · 6 holders · USD 96.06
- 2026 Q1: USD 1,949,875,515 · 7 holders · USD 86.65
- 2026 Q2: USD 2,069,120,161 · 7 holders · USD 78.23
- 2026 Q3: USD 36,813,000 · 1 holder · USD 86.29